ID   HEK293-CAGA
AC   CVCL_ZD63
SY   HEK293 (CAGA)12
DR   Wikidata; Q98126665
RX   PubMed=22052913;
RX   PubMed=22593183;
RX   PubMed=23543431;
CC   Characteristics: Robustly responds to signaling by activin and TGF-beta class ligands and employed in an assay measuring inhibition of ligand activity (PubMed=23543431).
CC   Characteristics: Luciferase reporter gene expression is under the control of a promoter containing a Smad binding element (SBE) (CAGA(12)).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0045 ! HEK293
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 5
//
RX   PubMed=22052913; DOI=10.1074/jbc.M111.270801;
RA   Cash J.N., Angerman E.B., Kattamuri C., Nolan K., Zhao H.-Y., Sidis Y.,
RA   Keutmann H.T., Thompson T.B.;
RT   "Structure of myostatin.follistatin-like 3: N-terminal domains of
RT   follistatin-type molecules exhibit alternate modes of binding.";
RL   J. Biol. Chem. 287:1043-1053(2012).
//
RX   PubMed=22593183; DOI=10.1210/me.2012-1061;
RA   Cash J.N., Angerman E.B., Keutmann H.T., Thompson T.B.;
RT   "Characterization of follistatin-type domains and their contribution
RT   to myostatin and activin A antagonism.";
RL   Mol. Endocrinol. 26:1167-1178(2012).
//
RX   PubMed=23543431; DOI=10.1177/1087057113482585;
RA   Cash J.N., Angerman E.B., Kirby R.J., Merck L., Seibel W.L.,
RA   Wortman M.D., Papoian R., Nelson S., Thompson T.B.;
RT   "Development of a small-molecule screening method for inhibitors of
RT   cellular response to myostatin and activin A.";
RL   J. Biomol. Screen. 18:837-844(2013).
//